Top

Drugs in R&D

Published in:

Open Access 01-06-2022 | Calcimimetic | Original Research Article

First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants

Authors: Fumihiko Koiwa, Rie Yazawa, Masafumi Fukagawa, Daisuke Honda, Tadao Akizawa

Published in: Drugs in R&D | Issue 2/2022

Abstract

Background and Objective

Upacicalcet sodium hydrate is a novel small-molecule calcimimetic and has potential as a therapeutic agent for secondary hyperparathyroidism. We assessed the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single intravenous dose of upacicalcet in Japanese healthy adults.

Method

This was a single-center, double-blinded, randomized, placebo-controlled, dose-escalation study. For each cohort, eight subjects were randomly assigned at a ratio of 3:1 to receive a single injection of placebo or upacicalcet 0.01, 0.1, 1.0, or 2.5 mg.

Result

The plasma concentration of upacicalcet increased in a dose-dependent manner. Upacicalcet rapidly disappeared from plasma after administration. The half-life of upacicalcet was approximately 1–2 h. The major excretion route of upacicalcet was via urine. Serum intact parathyroid hormone decreased in accordance with the upacicalcet dose, from the lowest dose of 0.01 mg. Gastrointestinal disorders occurred in one patient in the 1.0 mg group and in five patients in the 2.5 mg group. All adverse events were nonserious, and no symptomatic hypocalcemia occurred.

Conclusion

This study showed that upacicalcet acted as a calcimimetic and was excreted in the urine unchanged with little metabolism. Moreover, upacicalcet is a small molecule and has a small volume of distribution. In addition, less than 50% of upacicalcet binds to human plasma proteins. These findings suggest that upacicalcet administered to patients undergoing hemodialysis might be expected to have a long excretion period and sustained pharmacological effect.

Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913–21. https://doi.org/10.2215/CJN.06040710.CrossRefPubMed

Moorthi RN, Moe SM. CKD–mineral and bone disorder: core curriculum 2011. Am J Kidney Dis. 2011;58(6):1022–36. https://doi.org/10.1053/j.ajkd.2011.08.009.CrossRefPubMedPubMedCentral

Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol. 2011;15(6):797–809. https://doi.org/10.1007/s10157-011-0502-5.CrossRefPubMed

Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145–58. https://doi.org/10.1016/S0140-6736(09)60507-9.CrossRefPubMed

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18. https://doi.org/10.1097/01.ASN.0000133041.27682.A2.CrossRefPubMed

Fernández M, Morales E, Gutierrez E, Polanco N, Hernández E, Mérida E, et al. Calciphylaxis: beyond CKD–MBD. Nefrologia. 2017;37(5):501–7. https://doi.org/10.1016/j.nefro.2017.02.006.CrossRefPubMed

Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6(1):50–62. https://doi.org/10.2215/CJN.03940510.CrossRefPubMedPubMedCentral

Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001;59(3):1187–201. https://doi.org/10.1046/j.1523-1755.2001.0590031187.x.CrossRefPubMed

Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, EVOLVE Trial Investigators, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94. https://doi.org/10.1056/NEJMoa1205624.CrossRefPubMed

10.

Fukagawa M, Fukuma S, Onishi Y, Yamaguchi T, Hasegawa T, Akizawa T, et al. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clin J Am Soc Nephrol. 2012;7(9):1473–80. https://doi.org/10.2215/CJN.13081211.CrossRefPubMedPubMedCentral

11.

Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, et al. Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015;10(6):1031–40. https://doi.org/10.2215/CJN.07050714.CrossRefPubMedPubMedCentral

12.

Komaba H, Fukagawa M, KRN1493 Study Group. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Ther Apher Dial. 2008;12(1):44–9. https://doi.org/10.1111/j.1744-9987.2008.00631.x.CrossRef

13.

Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transpl. 2011;26(4):1327–39. https://doi.org/10.1093/ndt/gfq725.CrossRef

14.

Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol. 2008;3(6):1718–25. https://doi.org/10.2215/CJN.01040308.CrossRefPubMedPubMedCentral

15.

Fukagawa M, Shimazaki R, Akizawa T, Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018;94(4):818–25. https://doi.org/10.1016/j.kint.2018.05.013.CrossRefPubMed

16.

Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25. https://doi.org/10.1056/NEJMoa031633.CrossRefPubMed

17.

Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transpl. 2008;23(1):328–35. https://doi.org/10.1093/ndt/gfm534.CrossRef

18.

Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PloS Med. 2013;10(4):e1001436. https://doi.org/10.1371/journal.pmed.1001436.CrossRefPubMedPubMedCentral

19.

Y. Gincherman, K. Moloney, C. McKee, Coyne DW. Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int. 2010; 14(1); 68–72. https://doi.org/10.1111/j.1542-4758.2009.00397.x

20.

Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303–11. https://doi.org/10.2165/00003088-200948050-00002.CrossRefPubMed

21.

Eidman KE, Wetmore JB. Treatment of secondary hyperparathyroidism: how do cinacalcet and etelcalcetide differ? Semin Dial. 2018;31(5):440–4. https://doi.org/10.1111/sdi.12734.CrossRefPubMed

22.

Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2019;24(3):248–57. https://doi.org/10.1111/1744-9987.13434.CrossRefPubMedPubMedCentral

23.

Segawa H, Yamanaka S, Onitsuka A, Tomoe Y, Kuwahata M, Ito M, et al. Parathyroid hormone-dependent endocytosis of renal type Iic Na-Pi cotransporter. Am J Physiol Renal Physiol. 2007;292(1):F395-403. https://doi.org/10.1152/ajprenal.00100.2006.CrossRefPubMed

24.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156–64. https://doi.org/10.1001/jama.2016.19468.CrossRefPubMed

Title: First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants
Authors: Fumihiko Koiwa
Rie Yazawa
Masafumi Fukagawa
Daisuke Honda
Tadao Akizawa
Publication date: 01-06-2022
Publisher: Springer International Publishing
Keyword: Calcimimetic
Published in: Drugs in R&D / Issue 2/2022
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.1007/s40268-022-00385-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants

Abstract

Background and Objective

Method

Result

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and Objective

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2022

Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation

Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease

Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study

Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers

Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects